---
title: "Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: References"
description: "Reference list for the formulary evidence report on Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies. 68 cited documents."
canonical: "https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: References

<a id="references"></a>

## 5 References

1. [Abbott et al. (2024)](https://www.cambridge.org/core/elements/scn2arelated-disorders/ED2438A209BCDABCFC941E8C88803109)
2. [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)
3. [Andrews et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37577282/)
4. [Berg et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33236786/)
5. [Berg et al. (2024)](https://academic.oup.com/brain/article/147/8/2761/7656659)
6. [Berg et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39439575/)
7. [Berg et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12054743/)
8. [Berg et al. (2025c)](https://inchstoneproject.org/wp-content/uploads/2025/10/Berg-Priorities-EJPN-2025.pdf)
9. [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)
10. [ClinicalTrials.gov NCT05818553](https://clinicaltrials.gov/study/NCT05818553)
11. [Cohen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305579/)
12. [Conecker et al. (2024a)](https://onlinelibrary.wiley.com/doi/10.1111/epi.17991)
13. [Conecker et al. (2024b)](https://onlinelibrary.wiley.com/doi/full/10.1111/epi.17992)
14. [Cutts et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35325842/)
15. [Dalby et al. (2022)](https://praxismedicines.com/wp-content/uploads/2023/09/Dalby_AES2022_SCN2A_Final_Approved_QR.pdf)
16. [Densmore et al. (2021)](https://praxismedicines.com/wp-content/uploads/2023/09/Densmore_SeizureExhibit_poster_final.pdf)
17. [Downs et al. (2024)](https://link.springer.com/article/10.1007/s11136-023-03543-6)
18. [DRKS DRKS00032614](https://drks.de/search/en/trial/DRKS00032614)
19. [FamilieSCN2A Foundation](https://www.scn2a.org/scn2a-related-disorders/clinical-information/)
20. [FDA Orphan Drug Designations and Approvals (2021)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=789620)
21. [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)
22. [Gallop et al. (2021)](https://www.sciencedirect.com/science/article/pii/S1525505021005850)
23. [GeneReviews](https://www.ncbi.nlm.nih.gov/books/NBK379665/)
24. [Gjerulfsen et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39812613/)
25. [Goad et al. (2025)](https://portal.findresearcher.sdu.dk/en/publications/development-and-adaptive-function-in-individuals-with-scn2a-relat/)
26. [Johannesen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29677576/)
27. [Johannesen et al. (2021)](https://air.unimi.it/bitstream/2434/949883/2/SCN8A.pdf)
28. [Kaat et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39887012/)
29. [Kahlig et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9304232/)
30. [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/)
31. [Kamireddy et al. (2025b)](https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension)
32. [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)
33. [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)
34. [Krey et al. (2022)](https://portal.findresearcher.sdu.dk/en/publications/current-practice-in-diagnostic-genetic-testing-of-the-epilepsies/)
35. [Ludwig et al. (2024)](https://inchstoneproject.org/wp-content/uploads/2025/11/Ludwig-et-al.-2024-Novel-approaches-to-measuring-cognition-in-individ.pdf)
36. [Ludwig et al. (2026)](https://link.springer.com/article/10.1007/s11136-025-04153-0)
37. [Magielski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11998016/)
38. [MedlinePlus](https://medlineplus.gov/genetics/condition/scn8a-related-epilepsy-with-encephalopathy/)
39. [Mesraoua et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41844481/)
40. [Neurology (2023)](https://www.neurology.org/doi/10.1212/WNL.0000000000202328)
41. [Oates et al. (2018)](https://www.nature.com/articles/s41525-018-0052-9)
42. [Pfister et al. (2022)](https://praxismedicines.com/wp-content/uploads/2023/09/Pfister_AES2022-SCN8A_Final_Approved_QR.pdf)
43. [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)
44. [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)
45. [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)
46. [Praxis Precision Medicines](https://praxismedicines.com/eap/)
47. [Praxis Precision Medicines Breakthrough Therapy designation announcement (2025)](https://praxismedicines.gcs-web.com/news-releases/news-release-details/praxis-precision-medicines-receives-fda-breakthrough-therapy)
48. [Praxis Precision Medicines EMBOLD results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embold)
49. [Praxis Precision Medicines EMBOLD topline results announcement (2024)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0)
50. [Praxis Precision Medicines EMBOLD topline results presentation (2024)](https://investors.praxismedicines.com/static-files/91013dac-4234-4f1e-8128-88e376d27b3b)
51. [Praxis Precision Medicines extension period announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html)
52. [Praxis Precision Medicines first quarter 2026 Form 10-Q (2026)](https://praxismedicines.gcs-web.com/static-files/b0705ab1-8493-4133-b5a3-366f9912cccd)
53. [Praxis Precision Medicines fourth quarter and full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/praxisye2025pr.htm)
54. [Praxis Precision Medicines NDA acceptance announcement (2026)](https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html)
55. [Praxis Precision Medicines NDA filing plans announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-plans-file-nda-relutrigine)
56. [Praxis Precision Medicines presentation (2025)](https://investors.praxismedicines.com/static-files/9e87e964-ab44-48df-9870-1553b639f479)
57. [Praxis Precision Medicines presentation (2026)](https://investors.praxismedicines.com/static-files/c2910f99-1668-45ca-8170-2471c172f2af)
58. [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340217/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html)
59. [Praxis Precision Medicines third quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/11/09/3398230/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2026-financial-results.html)
60. [Prime Therapeutics (2026)](https://www.primetherapeutics.com/quarterly-drug-pipeline-july-2026)
61. [SCN8A Research Consortium (2025)](https://link.springer.com/article/10.1186/s13023-025-03672-w)
62. [Sevinc et al. (2025)](https://inchstoneproject.org/wp-content/uploads/2025/11/The-Feasibility-of-Personalized-Endpoints-in-Asses.pdf)
63. [Tan et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70100)
64. [The Cute Syndrome Foundation](https://www.thecutesyndrome.com/clinicaltrials.html)
65. [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)
66. [Wolff et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28379373/)
67. [Xie et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40208090/)
68. [Zeng et al. (2022)](https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2022.809951/full)

## Related pages
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Terms and abbreviations](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations.md)
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Economic information and modeling report](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: prevalence by geography](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses.md)
